Market closedADR
Mesoblast/MESO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mesoblast
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Ticker
MESO
Sector
Trading on
Industry
Biotechnology
Headquarters
Melbourne, Australia
Employees
73
Website
Mesoblast Metrics
BasicAdvanced
$975M
Market cap
-
P/E ratio
-$0.09
EPS
2.38
Beta
-
Dividend rate
Price and volume
Market cap
$975M
Beta
2.38
52-week high
$9.91
52-week low
$1.61
Average daily volume
186K
Financial strength
Current ratio
1.18
Quick ratio
1.139
Long term debt to equity
21.325
Total debt to equity
24.757
Interest coverage (TTM)
-2.81%
Management effectiveness
Return on assets (TTM)
-5.41%
Return on equity (TTM)
-17.91%
Valuation
Price to revenue (TTM)
1,450.318
Price to book
3.06
Price to tangible book (TTM)
-15.44
Price to free cash flow (TTM)
-175.424
Growth
Revenue change (TTM)
-21.32%
Earnings per share change (TTM)
-15.34%
3-year revenue growth (CAGR)
-7.40%
3-year earnings per share growth (CAGR)
-18.27%
What the Analysts think about Mesoblast
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Mesoblast Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Mesoblast Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Mesoblast News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mesoblast stock?
Mesoblast (MESO) has a market cap of $975M as of October 26, 2024.
What is the P/E ratio for Mesoblast stock?
The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of October 26, 2024.
Does Mesoblast stock pay dividends?
No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Mesoblast dividend payment date?
Mesoblast (MESO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mesoblast?
Mesoblast (MESO) has a beta rating of 2.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.